Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

Complement regulatory protein Crry deficiency contributes to the
antigen specific recall response in experimental autoimmune
myasthenia gravis
Jindrich Soltys
Saint Louis University

Xiaobo Wu
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Soltys, Jindrich and Wu, Xiaobo, ,"Complement regulatory protein Crry deficiency contributes to the
antigen specific recall response in experimental autoimmune myasthenia gravis." Journal of
Inflammation. 9,. 20. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1246

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Soltys and Wu Journal of Inflammation 2012, 9:20
http://www.journal-inflammation.com/content/9/1/20

RESEARCH

Open Access

Complement regulatory protein Crry deficiency
contributes to the antigen specific recall response
in experimental autoimmune myasthenia gravis
Jindrich Soltys1* and Xiaobo Wu2

Abstract
Background: Myasthenia gravis (MG) and animal model of experimental autoimmune myasthenia gravis (EAMG) is
the most common autoimmune disorder of neuromuscular transmission. The disease is caused by the breakdown
of the acetylcholine receptor (AChR) which is largely due to complement activation at the neuromuscular junction
(NMJ). Limited knowledge exists to the extent that complement receptor 1-related gene/protein y deficiency
(Crry −/−) modulates the adaptive immune response and EAMG outcome.
Methods: Mouse EAMG was induced by s.c. administrations of purified acetylcholine receptor (AChR) to Crry −/−
and age- matched WT (C57BL/6) mice. Disease severity was assessed by clinical score assessment and muscle grip
strength measurements. Serum complement activity was determined by hemolytic assay. ELISA was used to detect
the level of AChR specific antibodies. Splenic cells were analyzed for T and B cells subsets distribution, release of
cytokines and AChR specific recall responses. Deposition of complement components at the NMJ was assessed by
immunofluorescence staining.
Results: In comparison to WT EAMG, Crry −/− EAMG mice showed signs of augmented muscle weakness but
differences, except for one time point, were not statistically significant. Serum complement activity was reduced in
Crry −/− EAMG mice and no substantial changes in deposition of C3, C3b/iC3b and C5b-9 (MAC) at the NMJ
between WT EAMG and Crry −/− EAMG mice were detected. Lack of Crry affected adaptive immune response.
Crry −/− EAMG mice showed increases in the number of AChR specific splenic T-cells secreting IFN-γ and IL-4.
Production of complement fixing antibodies (IgG2b, IgG2c) was also augmented. More Th1, Th2 and Th17 cytokines
were released into the bloodstream of Crry −/− EAMG mice.
Conclusions: Data suggest that Crry deficiency modulates the adaptive immune response in EAMG, but its effect
on disease outcome is limited. This was due to the generally lower serum complement level caused by increased
C3 turnover. Modulation of complement activity with soluble or membrane bound regulators of complement
activity represents a potentially effective approach to modify autoimmune processes in MG and EAMG.
Keywords: Acetylcholine receptor (AChR), Experimental autoimmune myasthenia gravis (EAMG), Complement
receptor 1-related gene/protein y deficiency (Crry −/−), Adaptive immune response
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Background
Myasthenia gravis (MG) is an autoimmune disorder in
which autoantibodies against nicotinic acetylcholine
receptors (AChR) trigger the destruction of the neuromuscular junction (NMJ). Three distinct mechanisms
are proposed to explain neuromuscular transmission
failure [1]. The AChR breakdown can be caused by a
direct block of receptor function which is primarily due
to antibodies that recognize the binding site for the cholinergic ligand. The other pathological mechanisms are
pointed to enhanced endocytosis and degradation of the
AChR triggered by antibody crosslinking, and complement mediated lysis of the NMJ.
The leading role for complement involvement in MG
pathogenesis is supported by multiple studies [2-4]. MG
patients show increased deposits of C3 and membrane
attack complex (C5b-9; MAC) at the NMJ [5-7] and
amplified complement consumption in vivo has also
been observed [8]. The simplified NMJ structure in MG
is a more likely consequence of complement mediated
injury [9].
The complement system plays an important role in innate immunity and mediates crosstalk between innate
and adaptive immunity [10]. There is a delicate balance
in vivo between complement activation and its inhibition. If this equilibrium is altered, the complement
system causes tissue injury and contributes to the pathogenesis of various diseases [11], including neurodegenerative disorders and other neuropathies [12]. Therefore,
complement activation is strictly controlled by the regulators of complement activity (RCA). Both membrane
bound and soluble RCA have the capacity to prevent the
exaggerated complement activation [13].
Limited knowledge is available regarding how specific
RCA affect the outcome of experimental autoimmune
myasthenia gravis (EAMG). In this study, we examined
the effect of complement receptor 1-related gene/protein
y deficiency (Crry −/−) on EAMG pathogenesis. Rodent
specific Crry has similar regulatory functions as human
decay accelerating factor (CD55/DAF) and membrane
cofactor protein (CD46/MCP) [14,15]. Crry is the only
ubiquitously expressed transmembrane protein with cofactor activity which is essential to control activation of
C3 complement component and protect self-tissues
from complement mediated lysis [16]. Crry −/− mice experience uncontrollable alternative pathway (AP) turnover in their plasma leading to an approximately 60%
reduction of serum C3 and factor B (fB). However, the
magnitude of AP mediated-complement consumption in
Crry −/− is less severe than those in fH−/− mice in which
over 90% of serum C3 was consumed in mice missing
this fluid phase complement regulator [17]. In contrast
to the spontaneous development of dense deposit glomerulonephritis in fH−/− mice, no renal pathology is
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documented in Crry −/− mice [14,18]. In addition, Crry
also has been shown to protect cells from complement
attack and is involved in T cell co-stimulation [19].
Based on previously described Crry regulatory properties, we hypothesized that lack of Crry in mice with
EAMG would lead to a more severe disease outcome.
The rationale was to examine the importance of the Crry
deficiency on EAMG pathology by comparing the clinical and immunological aspects of the disease in RCA
sufficient WT control (C57BL/6) and RCA deficient Crry
mice (Crry −/−). Our data show that Crry deficiency had
a direct impact on humoral and adaptive immune
responses. However, lack of Crry did not augment significantly disease severity in vivo.

Materials and methods
Mice

Crry +/− mice were generated by a standard gene targeting approach and were backcrossed into C57BL/6 background for over eight generations. Initial observations
showed that survival of Crry null embryos is compromised due to the uncontrollable complement activation
and concomitant placenta inflammation [20]. In order to
obtain viable Crry −/− mice (also called Crry single
knockout mice, Crry SKO), we utilized strategic breeding using female breeding partners with impaired complement (AP) capacity [14]. Crry −/− genotyping was
performed by PCR with primers of mCrry 16 TTGAGTT
CAATGCACTGAGGAGG, EcoRI 16 F CGCAGAATTC
AATCTCTTTTCT TTGCC and S46Neo GCTACCCGT
GATATTGCTGAAGAG. Wild-type (WT, C57BL/6)
mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Mice were housed and maintained in a
pathogen-free condition at the Saint Louis University
Department of Comparative Medicine. All experiments
were performed according to the protocols approved by
SLU IACUC.
Induction and clinical evaluation of experimental
autoimmune myasthenia gravis (EAMG)

The acetylcholine receptor was purified from the electric
organs of Torpedo californica (tAChR) by affinity chromatography [21]. Eight to ten weeks old WT and Crry −/−
male mice were used for experiments. EAMG was
induced by four subcutaneous injections of 20 μg tAChR
emulsified in complete Freund’s adjuvant (CFA) (Difco,
Voigt Global Distributions, KS) in a total volume of
200 μl. Mice were immunized along the back subcutaneously, at the base of the tail and boosted twice with
20 μg of tAChR in incomplete Freund’s adjuvant 4 and
8 weeks after primary immunization. Control mock
immunized mice received an equal volume of PBS in
CFA or IFA.
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To validate disease induction in WT and Crry −/− mice
were bled ten days after primary and secondary
immunization. Sera were collected and screened by
ELISA for the production of AChR specific antibodies.
EAMG outcome was assessed on a weekly basis. All mice
were clinically scored [22], weighed and examined for
muscle weakness. Measurements were performed with a
grip strength meter (Columbus Instruments, Columbus,
OH) and DFE digital force gauge (Ametek, Largo, FL)
was used to detect the peak force when animals grasp
a grid pull bar. Prior to the measurement, each mouse
was exercised with 10–20 paw grips and then the final
5 grips were recorded and analyzed.
Complement activity

Complement activity in WT EAMG, Crry −/− EAMG
and mock immunized WT Ctrl, Crry −/− Ctrl mice were
analyzed one week after the primary or secondary
immunization (Day 8, 35) and at the end of experiment
(Day 63). Serum diluted 1:10, 1:20, 1:40 and 1:80 in Veronal buffer was analyzed by a CH50 hemolytic assay
according to the manufacturer’s protocol (Sigma, St.
Louis, MO). Briefly, 100 μl of 2 × 108 sensitized sheep
erythrocytes were mixed with pre-diluted serum and
then incubated for 60 minutes at 37°C. At the end of the
incubation time, un-lysed cells were removed by centrifugation (Sorvall Legend RT+ benchtop centrifuge: 1500
RPM for 5 minutes) and the intensity of complement
mediated hemolysis was measured at 412 nm on Tecan
Infinity M200 reader (Tecan Group Ltd., Durham NC).
ELISA for AChR specific IgG subclasses

Conventional ELISA was used for the detection of antiAChR specific complement fixing antibodies. Serum
levels of AChR antibodies were examined at Days 10, 35
and 63 post primary immunization (p.i.). A 96 well Nunc
plates (Fisher Scientific, Pittsburgh, PA) were coated
overnight at 4°C with 10 μg/ml of purified AChR
(100 μl/well). After three washes with PBS-Tween, the
plates were blocked for 2 hrs at room temperature (RT)
with 200 μl PBS Tween 20 (Sigma, Saint Louis, MO).
Mouse serum samples in triplicates at dilution of 1:500
were added (100 μl/well) and incubated at RT for 90
minutes. After washes with PBS-Tween, the plates were
incubated for another 90 min with HRP conjugated goat
anti-mouse Abs (IgG, IgG1, IgG2b, IgG2c; 1:2000; Alpha
Diagnostics, San Antonio, TX). The color reaction was
developed with SureBlue TMB substrate and stopped
with TMB stop solution (KPL Inc., Gaithersburg, MA).
Stopped reactions were read on a Tecan Infinity M200
reader (Tecan Group Ltd., Durham NC). Absorbances
were measured at 450 nm and the results were
expressed in O.D. values.
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Immunofluorescence detection of C3, C3b/iC3b and C5b-9
(MAC) complement components

Mouse diaphragms were embedded in OCT Compound
Tissue-Tek (Fisher Scientific, Pittsburgh, PA) and were
frozen in liquid N2-cooled 2-methybutane. Tissue samples were stored at −80°C until usage. For IHC analysis
of C3, C3 fragments (C3b/iC3b/C3c) and C5b-9 deposition at the NMJ, 10 μm cryosections of mouse diaphragms were mounted on SuperfrostPlus slides. Slides
were allowed to air dry and tissues were fixed in cold
acetone for 5 minutes. After three washes with PBS, sections were blocked with 3% BSA in PBS for at least 1
hour. Tissues were further stained with FITC conjugated
anti-mouse C3 antibody (MP Biomedicals, Solon, OH).
For recognition of C3b/iC3b/C3c rat anti-mouse monoclonal antibody (clone 3/26; Hycult Biotech, Plymouth
Meeting, PA) and rabbit anti-mouse C5b-9 (EMD Biosciences, San Diego, CA) polyclonal antibodies were used.
Although antibody 3/26 recognizes C3b/iC3b/C3c, soluble C3c is not present on the cell surfaces [23]. All
these primary antibodies were diluted at 1:200 and
1:300, respectively. For C3b/iC3b and C5b-9 (MAC)
staining, sections were labeled with Alexa488 conjugated
goat anti-rat and goat anti-rabbit secondary antibodies
(1:500; Invitrogen, Carlsbad, CA), respectively. Finally,
Alexa Fluor596 labeled bungarotoxin (1:1000; BTX, Invitrogen, Carlsbad, CA) was used to visualize the NMJ.
After washes, sections were viewed by an Olympus
fluorescence microscope (Olympus Inc, USA). Captured
microphotographs were analyzed with Image Pro software (Media Cybernetics, Silver Springs, MD). Results
were expressed as percentage of C3 fragments and C5b9 deposits present at the BTX labeled NMJs.

ELISPOT

Plates coated with primary capture antibodies specific
for IFN-γ and IL- 4 from BDTM Elispot Kits (1:200; BD
Biosciences, San Jose, CA) were used for detection of
cytokine secreting cells. Single cell suspensions (5 × 105/
well) of splenocytes in 100 μl of complete RPMI-1640
medium were added in triplicate and incubated for 24
hours, with or without recall antigen of tAChR (at the
concentrations of 10; 1.0; 0.1 and 0.01 μg/well). After
washes with PBS-Tween buffer, cells were stained
overnight with secondary biotin labeled anti-IFN-γ and
IL-4 antibodies. After three washes with PBS-Tween
buffer, streptavidin-HRP was added and plates were
incubated for 60 minutes. ELISPOT plates were developed with BDTM ELISPOT AEC substrate sets (BD
Biosciences, San Jose, CA). Spots were counted on
Immunospot Image Analyzer using Beta 4.0 version
software (ELISPOT Image Analyzer, Cellular Technology Ltd., Cleveland, OH).
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FACS analysis

Distribution of T and B cells subsets was analyzed by
Becton Dickinson FACSCalibur flow cytometer or FACSArray Bioanalyzer according to the manufacturer’s
protocol (BD Biosciences, San Jose, CA). Splenic cell
suspensions were harvested at Day 63 post primary
immunization and stained with antibodies specific for T
(CD3E PE-Cy7, CD4 PE, CD8 APC) and B (CD45R/B220
PE-Cy7, CD23 PE, sIgM APC) cell subsets markers (BD
Biosciences, San Jose, CA). Data were analyzed with
WinlistTM software (Verity Inc., Sunnyvale, CA).
Cytometric beads array (CBA)

The BDTM CBA Mouse Th1/Th2/Th17 Cytokine Kit (BD
Biosciences, San Jose) was used to measure IL-2; IL-4,
IL-6, IFN-γ, TNF and IL-17 protein levels. The procedure was carried out according to the manufacturer's
protocol (CBATM, BD Biosciences, San Jose, CA). Serum
samples from individual mice were collected at Day 63
p.i. Total 25 μl of serum was mixed with 25 μl of assay
diluent. Then, 50 μl of cytokines capture beads and
50 μl of PE-labeled detection antibody were added to
each diluted serum and incubated for 2 hrs at RT. Cytokine standard solutions from the BDTM CBA Kits were
diluted from concentrations of 0 to 5000 pg/ml. After
incubation in the dark at RT for 2 hours, all cytokine
standards and samples were washed twice with buffer.
Finally, bead pellets with captured cytokines were resuspended in 300 μl of wash buffer and read on BD FACSArray Analyzer (BD Biosciences, San Jose, CA).
Acquired data were further analyzed with FCAP ArrayTM
software (Soft Flow Inc. Minneapolis, MN).
Statistical analysis

To compare all groups of data, experimental groups
were evaluated by a Two-way ANOVA followed by the
Bonferroni post hoc test. Column analyses were performed by Mann - Whitney test. Data are presented as
the mean ± SEM where P values < 0.05 are considered
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statistically significant. Data analysis was performed
using GraphPad Prism version 5.04 for Windows
(GraphPad Software, San Diego, California, USA).

Results
Development and progression of disease in WT EAMG
and Crry −/− EAMG mice

To permit satisfactory statistical analysis, disease outcome in WT EAMG and Crry −/− mice was determined
by three independent experiments with 5–9 mice in each
experimental group. Mouse weight and grip strength in
WT EAMG, Crry −/− EAMG (tAChR) and mock (PBS)
immunized controls of WT, Crry −/− mice were
assessed for the period of 9 weeks after the primary
immunization. We did not detect significant changes in
weight loss between WT EAMG and Crry −/− EAMG
mice (Figure 1a). Muscle grip strength varied between
WT and Crry −/− mice. In general, Crry −/− EAMG mice
(Figure 1b) appeared to be weaker than their WT
EAMG counterparts (Figure 1c). Crry −/− mice showed
signs of augmented muscle weakness in an EAMG but
the differences, except for one time point (Day 42 p.i.),
were not statistically significant (Figure 1d). In addition,
Crry −/− EAMG mice exhibited no acceleration in disease progression. Furhermore, clinical score analysis correlated with our muscle grip strength data in which no
differences between RCA deficient (Crry −/− EAMG) and
RCA sufficient (WT EAMG) mice (Table 1) were
observed.
Serum complement activity

Crry protein has been shown to regulate classical and alternative complement pathways [24] and Crry −/− mice
have reduced C3 and fB concentrations due to complement consumption through uncontrolled complement
alternative pathway (AP) turnover [14]. A standard
hemolytic assay was employed to measure complement
activation of WT EAMG and Crry −/− EAMG mice.
Examining WT EAMG and Crry −/− EAMG serum at

Figure 1 a, b, c, d. Deficiency of Crry −/− did not alter extensively the clinical outcome of EAMG. Mice were immunized with 20 μg of
tAChR or PBS at the times indicated with arrows ("). Weight loss (Figure 1a) and muscle grip strength (Figure 1b, c, d) measurements were used
to assess the clinical outcome of EAMG. See Material and Methods for experimental details. Data shown are one of three independent
experiments. Error bars indicate ± SEM values; n = 5–9 mice per group. Asterisks (*) on top of the time points indicate statistically significant
differences between WT EAMG and Crry −/− EAMG mice (p < 0.05).
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Table 1 WT EAMG and Crry −/− EAMG mice show similar
disease outcome
Mouse strain

Day 0

Day 14

Day 35

Day 63

WT EAMG

0

0.400 ± 0.22

1.000 ± 0.35

1.300 ± 0.57

Crry −/− EAMG

0

0.375 ± 0.25

0.875 ± 0.25

1.250 ± 0.50

WT Ctrl

0

0

0

0

Crry −/− Ctrl

0

0

0

0

EAMG clinical scores were determined at Day 0 (prior disease induction), Days
14, 35 and 63 post primary immunization. The data for each mouse strain
represent the average (± SEM) in one of three representative experiments
(n = 5–9 mice per group). Despite greater general weakness in Crry −/− EAMG,
no significant changes in disease clinical scores were detected.

dilutions 1:10; 1:20; 1:40; 1:80, collected at different days
after disease induction (Day 8, 35 and 63 p.i.), we
observed that total complement activity in Crry −/−
EAMG mice at dilution 1:10 was about 20-40% lower
when compared to the complement regulator sufficient
WT EAMG mice. Complement levels in Crry −/− EAMG
mice remained low at Days 8 and 35 (Figure 2a, b). At
day 63 p.i. WT EAMG and Crry −/− EAMG mice
showed reduced complement titers (Figure 2c). Disease
induction in Crry −/− EAMG mice did not augment
complement activity in blood serum. This was possibly
due to a complex issue where in Crry −/− mice an uncontrolled complement turnover and a major membrane
complement regulator deficiency exists at the same time.
Levels of AChR specific IgG antibodies

Next, we examined the effect of Crry deficiency on the
production of anti-AChR antibodies where the levels of
specific antibody subclasses (IgG, IgG1, IgG2b, IgG2c)
were measured by ELISA at Day 10, 35 and 63 post primary immunization (p.i.). As shown on Figure 3a (Day
63 p.i.), the total amount of anti-AChR IgG antibody
was elevated in Crry −/− EAMG. While the IgG1 levels
were comparable between the WT and Crry −/− groups
(Figure 3b), the production of complement fixing antibodies IgG2b (Figure 3c) and IgG2c (Figure 3d) in Crry −/−
EAMG mice was significantly increased. Similar patterns

in the AChR specific antibodies profile, but to a lesser
magnitude, was observed on Day 10 and seven days after
the secondary immunization (AChR + IFA; Day 35 p.i.).
Mock immunized mice (PBS + CFA or PBS + IFA) did
not generate any measurable levels of anti-AChR
antibodies.
Immunofluorescence staining for the deposition of C3, C3
fragments (C3b/iC3b) and C5b-9 (MAC) at the NMJs

As a result of augmented production of complement fixing antibodies (IgG2b, IgG2c) in Crry −/− EAMG mice, a
significant deposition of IgG and subsequent complement activation at the NMJs were expected. Complement deposition at the NMJs was assessed by staining
for C3, C3 fragments (C3b/iC3b) and C5b-9 (MAC).
Despite the overall lower complement activity in blood
serum of Crry −/− mice, diaphragms from WT EAMG
and Crry −/− EAMG showed similar deposition of C3
(Figure 4a, b) and C3 fragments (C3b/iC3b; Figure 4d, e).
Interestingly, strong presence in complement components at the NMJs of WT EAMG and Crry −/− EAMG
mice did not result in effective MAC formation (C5b-9;
Figure 4c, f ). Quantitatively, we did not find any significant differences in deposition of C3, C3b/iC3b fragments and C5b-9 (MAC) at the NMJ of WT EAMG and
Crry −/− EAMG mice (Figure 5). Mock (PBS) immunized WT and Crry −/− mice did not exhibit any IgG or
complement components deposition at the NMJ (data
not shown).
Specific recall responses to the AChR antigen

Furthermore, we investigated the effect of Crry
deficiency on the development of the adaptive immune
response in actively induced EAMG. The recall response of splenic T cells to the AChR antigen was
determined by ELISPOT assay on Day 63 post primary
immunization. At this time point, the frequency of
tAChR responding cells isolated from WT EAMG and
Crry −/− EAMG was considerably different. Crry −/−
EAMG mice have more IFN-γ (Figure 6a) and IL-4

Figure 2 a, b, c. Crry −/− mice have decreased complement activity during actively induced EAMG. Complement activity was measured at
Day 8, 35 and 63 (Figure 2a, b, c) by complement hemolytic assay. See Material and Methods for experimental details. Data is representative of
three independent experiments. All error bars are ± SEM. Asterisks (*) on top of the time points indicate statistically significant differences
between WT EAMG and Crry −/− EAMG mice (p < 0.05).
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Figure 3 a, b, c, d. The level of anti-AChR specific complement fixing antibodies IgG2b and IgG2c is augmented in Crry −/− EAMG mice.
The amount of antibodies produced was determined by ELISA and the level of anti-AChR antibodies production is expressed in O.D. Blood serum
from WT EAMG and Crry −/− EAMG mice was collected at Day 63 p.i. Data shown represent one of three independent experiments. Error bars
indicate ± SEM values; Asterisks on the top of the bars (*, **) represent statistically significant difference at p < 0.05 and p < 0.01.

(Figure 6b) positive cells than WT EAMG mice. The
numbers of spots were increased in a dose dependent
fashion when recall antigens were provided at a dose
of 10.0, 1.0, 0.1 μg/ml of tAChR. Re-stimulation of
control (PBS) immunized Crry −/− and WT cells with
tAChR showed no spot formation. Stimulation with
Con A (1 μg/ml) resulted in development of a comparable number of spots in both complement regulator

deficient (Crry −/−) and complement regulator sufficient WT mice (data not shown).
T and B cells subsets distribution in WT EAMG and
Crry −/− EAMG

We have also examined if established EAMG affects T
and B cell subset distribution in Crry −/− mice. T and B
cell subset analysis was performed in WT EAMG and

Figure 4 a, b, c, d, e, f. Decreased complement activity in blood serum of Crry −/− EAMG mice did not alter the amount of complement
deposition at the NMJs. Diaphragms from WT EAMG (Figure 4 a, b, c) and Crry −/− EAMG (Figure 4 d, e, f) mice were stained for the presence
of C3, C3b/iC3b and C5b-9 (green fluorescence) complement components. The NMJs were visualized with bungarotoxin (BTX; red fluorescence).
Not immunized WT Ctrl and Crry −/− Ctrl mice did not show complement deposition at the NMJ (data not shown). Diaphragms of a minimum of
5 mice from each experimental group were analyzed. Scale bars for magnification (20 μm) are shown on each microphotograph. See Material
and Methods for experimental details.
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Th1, Th2 and Th17 cytokine production in EAMG

Figure 5 Deposition of C3, C3b/iC3b and C5b-9 (MAC) is similar
at the NMJs of WT EAMG and Crry −/− EAMG mice. Diaphragms
from WT EAMG and Crry −/−EAMG mice were stained for C3, C3b/
iC3b and C5b-9 (MAC) and BTX staining was used to visualize the
NMJs. The results are expressed as percentage of NMJ (%) with
detected complement deposits. Minimum three sections with 10–15
NMJs from each diaphragm were quantified (n = 5 mouse per
experimental group).

Crry −/− EAMG mice by flow cytometry at Day 63 post
immunization. As a control, we also included WT and
Crry −/− mice without disease induction. WT EAMG
and Crry −/− EAMG mice had comparable T cell subset
distribution (Figure 7a). Repeated immunization with
tAChR did not have direct effect on T and B cell subset
distribution (Day 63). However, the percentage of B cells
in the spleen of Crry −/− mice was reduced (Figure 7b).
Decline in B cell population was not related to the
EAMG.

We investigated whether there were any differences in
production of Th1, Th2 and Th17 cytokines followed by
tAChR immunization. While only pro-inflammatory
cytokines (IL-6 and TNF) were detected in WT Ctrl
mice (Figure 8a), blood serum of Crry −/− Ctrl mice
showed small increases in levels of IL-2, IL-4, IL-6, IFNγ and IL-17. In comparison to the WT Ctrl, Crry −/− Ctrl
and WT EAMG the highest serum cytokines concentrations were detected in Crry −/− EAMG mice (Figure 8b).
Crry deficiency in EAMG was associated with increased
serum levels of the pro-inflammatory TNF as well as IL2, IL-4, IL-6 and IL-17. In average Crry −/− EAMG mice
showed about two to three folds increase in serum cytokines concentration (Table 2). We assume that increase
in IL-6 and TNF cytokine levels in WT Ctrl mice was
caused by repeated immunizations with complete and
incomplete Freund’s adjuvant (PBS + CFA, PBS + IFA).

Discussion
Our study shows that lack of Crry in EAMG is associated with altered humoral and adaptive immune
responses. Crry deficiency enhanced the production of
complement fixing antibodies (IgG2b, IgG2c) and augmented specific recall responses in vitro. Production of
Th1, Th2 and Th17 cytokines was also increased. In
comparison to WT EAMG, Crry −/− EAMG mice
showed symptoms of induced muscle weakness but this
difference, except one time point, did not reach a statistical significance. This result was probably due to a
unique situation where simultaneously Crry deficiency
and reduced amount serum C3 and fB levels occur in
Crry −/− mice.
Analysis of splenocytes from Crry −/− EAMG mice
demonstrated that there were significant changes in the
frequency of IFN−γ and IL-4 secreting cells after the restimulation with tAChR. It is well established that IFN-γ

Figure 6 a, b. Crry −/− EAMG mice show augmented IFN-γ and IL-4 recall responses to tAChR ex vivo. Splenic cell suspensions (105 cells/
well) isolated from WT EAMG and Crry −/− EAMG mice were re-stimulated in triplicate with tAChR at concentrations of 10, 1.0, 0.1, and 0.01 μg/ml.
The frequency of IFN-γ and IL-4 secreting cells was determined by ELISPOT assay and additional controls for negative or positive spot production
were established. Con A (1 μg/ml) treated cells (positive control) generated comparable number of spots in all experimental groups (243 ± 57 WT
and 211 ± 36 Crry −/−), whereas PBS immunized (negative control) mice did not have any spots. Results shown are representative of two
independent experiments. Asterisks (*) represent statistically significant differences at p < 0.05.
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Figure 7 a, b Induction of EAMG in Crry −/− and WT mice did not affect the distribution of T and B cell subsets. Splenic cell suspensions
from tAChR and mock immunized mice were analyzed by Flow cytometry at Day 63. Results are expressed as percentage of positive cells for
each marker (CD3E PE-Cy7, CD4 PE, CD8 APC, CD45R/B220 PE-Cy7, CD23 PE, sIgM APC; BD Biosciences). Results shown are representative of two
independent analyses (n = 4–7 mice per group).

and IL-4 play a critical role in the pathogenesis of
EAMG. IFN-γ knockout mice showed dramatic reduction in mouse AChR-specific IgG1 and IgG2a antibodies
and were resistant to EAMG [25]. A recent study on rat
myocytes suggests that the IL-4 receptor provides a link
between the immune system and muscle in EAMG [26].
Overproduction of IL-6 also plays an important role in
age related pathogenic mechanisms mainly in earlyonset of MG [27]. This corroborates with the evidence
of steroids preventing MG crisis through their effect on
down-regulating IL-6 [28]. In summary, pro-inflammatory cytokines affect the AChR expression and contribute
to the initiation of the autoimmune response [29]. We
found that levels of IL-2, IL-4, IL-6, TNF, and IL-17
cytokines were elevated in serum of Crry −/− EAMG
mice. Similarly to Mu et al. we showed that the cytokine
balance is rearranged during disease development and
IL-17 is involved in EAMG [30].
However, increased number of IFN-γ and IL-4 cells in
Crry −/− EAMG had a restricted impact on the clinical
outcome of EAMG in our current study. In comparison
to the previous studies that EAMG model was performed
on a C3 sufficient background, we assume that this was
due to decreased complement activity in Crry −/− mice

affecting both innate and adaptive immune responses.
Despite lowered complement activity in bloodstream of
Crry −/− mice, we observed that there was considerable
deposition of C3 and cleaved C3 fragments (C3b/iC3b) at
the NMJ of Crry −/− EAMG mice. If Crry −/− mice have a
normal level of complement, the uncontrolled complement activation would result in a more severe form of
tissue injury.
Our current observation and the studies by Heeger et
al [31] on decay accelerating factor (DAF) deficient mice
support the idea that regulators of complement activity
impact adaptive immune response [32]. Their significant
finding is that the enhanced production of IL-2 and
IFN-γ by DAF −/− T cells after re-stimulation is largely
complement dependent. Pavlov and colleagues reported
similar findings that splenic cells from DAF deficient
mice proliferated more vigorously following in vitro
stimulation with allogeneic cells [33]. The essential role
of both complement regulators, Crry and DAF in preventing of tissue injury was validated in vivo on antibody
induced autoimmune glomerulonephritis [34].
The important role of RCA complement regulatory
proteins in EAMG pathogenesis is probably through
their functions on altering adaptive immune responses

Figure 8 a, b. Levels of Th1, Th2 and Th17 cytokines are increased in plasma of Crry −/− EAMG. Ex vivo cytokine production from blood
plasma collected at Day 63 p.i. from mock immunized WT and Crry −/− mice and tAChR immunized mice (WT EAMG and Crry −/− EAMG) was
analyzed with cytometric bead arrays (CBA, BD Biosciences). Individual cytokine concentrations are shown in pg/ml. Asterisks (*) indicate values
p < 0.05 between complement regulator sufficient WT and complement regulator deficient Crry −/− mice (Figure 6a - Ctrl, Figure 6b - EAMG).
Results shown are representative of three independent analyses (n = 4–6 mice per experimental group).
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Table 2 Cytokine induction ratio is increased in Crry −/−
EAMG mice
Cytokine (fold increase)

TNF

IL-4

IL-6

IL-17

Crry −/− EAMG / WT EAMG

3.17

3.27

2.71

2.74

Crry deficiency in EAMG was associated with increased serum levels of the
pro-inflammatory TNF as well as IL-4, IL-6 and IL-17. Cytokine induction ratio
(fold increase) in Crry −/− EAMG group was calculated as follows. An average
serum cytokine concentration in Crry −/− EAMG was divided by serum cytokine
concentration in WT EAMG mice (Day 63 post primary immunization).

[35,36]. Results from our study show that Crry deficiency modulates antigen specific response in EAMG.
However, the detected changes in humoral and adaptive
immune response did not eventually lead to the development of an augmented severe disease phenotype. This is
in contrast with studies when mice overexpressing Crry
or a soluble form of Crry (Crry-Ig) were used for inhibition of complement activity and disease prevention
[37,38].
Currently, it is still a challenge for us to fully understand to what extent and how deficiency in specific RCA
affects humoral and adaptive immune response in MG
and EAMG. Ours and the others data suggest that there
is systemic and indirect effect of complement on T cell
immunity [39]. Additional evidence indicates that different expression of RCA in muscle could affect the outcome of EAMG. In passively induced EAMG, the
expression of Crry and DAF is increased at diaphragm
junctions, whereas more DAF and less of Crry is present
at the extraocular muscle junctions. This distinctive pattern in Crry and DAF distribution may contribute to the
higher susceptibility of eye muscle to MG [40].

Conclusions
Our observations point to two important biological consequences linked with Crry deficiency and EAMG
pathogenesis. Crry −/− mice have impairment in membrane -related inhibition of complement activation and
show failure in controlling complement homeostasis.
However, Crry participates in crosstalk between the innate and adaptive immune response. We propose that
modulation of complement activity with different soluble
or membrane bound regulators of complement activity
represents a potentially effective way to modify autoimmune processes in MG and EAMG.
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